BML Capital Management »

Achilles Therapeutics shares owned by BML Capital Management

Quarter-by-quarter ownership of Achilles Therapeutics (ACHL) shares owned by BML Capital Management from 13F filings

Historical chart of BML Capital Management investment in Achilles Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Achilles Therapeutics held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Achilles Therapeutics by BML Capital Management

Quarter filed Position value Share count Share price at filing
2025-03-31 $0 3.8M 0.00
2024-12-31 $4.7M 4.1M 1.14
2024-09-30 $4.2M 4.1M 1.02
2024-06-30 $510k 625k 0.82

More positions owned by BML Capital Management

Aclaris Therapeutics (ACRS)
Atea Pharmaceuticals (AVIR)
Adverum Biotechnologies Com New (ADVM)
Instil Bio Com New (TIL)
Oramed Pharmaceuticals Com New (ORMP)
Pmv Pharmaceuticals (PMVP)
Alumis (ALMS)
Lava Therapeutics Nv SHS (LVTX)
Kezar Life Sciences Com New (KZR)
Connect Biopharma Hldgs SHS
Imagenebio
Athira Pharma
Astrotech Corp (ASTC)
Target Corporation (TGT)
Vistagen Therapeutics Ord (VTGN)

View all positions for BML Capital Management

Top funds holding Achilles Therapeutics

Rhumbline Advisers
GAMMA Investing

View all funds holding Achilles Therapeutics